Generate Investment Management Ltd Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Generate Investment Management Ltd bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, Holdings Channel.com reports. The fund bought 42,042 shares of the medical research company’s stock, valued at approximately $8,262,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Private Trust Co. NA grew its stake in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after buying an additional 47 shares during the last quarter. Clear Harbor Asset Management LLC grew its holdings in IQVIA by 1.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after buying an additional 50 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its holdings in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after buying an additional 50 shares during the last quarter. Fortitude Family Office LLC increased its position in IQVIA by 2.9% during the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after acquiring an additional 56 shares during the period. Finally, Huntington National Bank lifted its stake in shares of IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.9 %

NYSE:IQV opened at $208.13 on Friday. The business’s 50-day moving average price is $200.53 and its two-hundred day moving average price is $219.80. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 2.15 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on IQV shares. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Wednesday, December 11th. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Redburn Atlantic assumed coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Finally, Truist Financial dropped their price objective on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $252.39.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.